Nicotine has become linked with the deepest harms associated with smoking, even though the chemical itself does not drive the cancers or lung illnesses produced by burning tobacco.
Easthampton recently joined the ranks as the 25th municipality in Massachusetts to adopt a “nicotine-free generation” policy. People born after January 1, 2006 will forever be barred from legally purchasing nicotine products there. The prohibition extends beyond cigarettes to include noncombustible nicotine items that can aid smokers in lowering their risk.
For decades, anti-smoking campaigns have dramatically curtailed cigarette use, particularly among the youth. That progress is welcome. Yet nicotine itself has become associated with the worst consequences of smoking, even though the chemical is not the cause of cancers, lung disease, or the majority of cardiovascular problems tied to burning tobacco. Worse, the movement against nicotine has swung to such an extreme that it threatens to criminalize some of the most effective aids for quitting smoking.
Take into account the reports that Marty Makary stepped down as FDA commissioner to oppose the White House’s decision to authorize flavored nicotine vaping products. These devices do not involve combustion—another core health hazard of smoking—and they could help adults transition away from cigarettes. If Makary aimed to shield Americans from tobacco’s most severe health risks, targeting vaping is not the right strategy. The core issue is smoking; vaping, comparatively, poses fewer hazards.
Public health agencies have spent countless years fighting smoking, to the point of viewing nicotine itself as the adversary. In hindsight, that interpretation is understandable. If nicotine is what makes smoking appealing, some argue, then nicotine must be the problem. Yet the link between nicotine and smoking-related disease is far more intricate than most people appreciate.
In 2015, Britain’s Royal Society for Public Health, not exactly known for a permissive medical stance, characterized nicotine as “no more harmful to health than caffeine.” That framing may surprise many Americans, but it underscores a key reality. Nicotine is the addictive element of tobacco cigarettes, but it is not the cause of lung cancer or emphysema. The damages stem mainly from inhaling combustion products—tar, carbon monoxide, and thousands of toxic chemicals produced by burning tobacco.
Moreover, an expanding body of research hints that nicotine may confer benefits that public discussions rarely acknowledge.
Nicotine as a Cognitive Tool
Millions of adults reach for nicotine for the same reason many reach for caffeine: they believe it helps them think more clearly, focus more intently, and manage daily pressures more effectively.
The pharmacology is surprisingly akin to caffeine. Both substances are stimulants. Nicotine enhances alertness and concentration. It can bolster attention and quicker responses. Unlike caffeine, nicotine often appears to have calming effects, increasing beta-endorphin release and aiding many users in coping with stress and anxiety. The familiar line “I need a cigarette” can reflect habit as well as nicotine’s tension-relieving properties.
Researchers have observed that nicotine can sharpen attention, working memory, and episodic memory in both users and nonusers. Studies have linked nicotine use with better short-term verbal memory and faster learning among older adults. Other research hints that nicotine may assist people diagnosed with schizophrenia in compensating for cognitive impairments that hinder daily functioning, which could help explain the particularly high smoking rates in that group.
Investigations have also examined nicotine’s potential role in mitigating symptoms of attention-deficit/hyperactivity disorder (ADHD). An expanding corpus of evidence indicates nicotine can enhance attention, inhibitory control, and facets of executive functioning. A 1996 review published in Psychopharmacology concluded that the drug “may be useful in treating the symptoms of ADHD.” More recently, a 2017 literature synthesis reported that nicotine has been shown to improve focus and reduce inattentive symptoms in individuals with the disorder. Nicotine is not an approved ADHD treatment, and the evidence remains preliminary. Yet the existence of this research complicates the common portrayal of nicotine as a substance devoid of any positive effects.
Taken together, these findings imply that many nicotine users do more than merely satisfy a craving—they may be gaining beneficial effects.
This should come as no surprise. People have always sought substances that enhance performance, lift mood, sharpen concentration, ease fatigue, or ease stress. Billions consume coffee, tea, and other caffeinated beverages precisely for these reasons.
Researchers have also explored nicotine’s potential involvement in conditions ranging from Parkinson’s disease and Alzheimer’s disease to ulcerative colitis and age-related cognitive decline. Not all outcomes are conclusive. Some lines of inquiry yield conflicting results. Others remain preliminary. No responsible observer would label nicotine a miracle drug.
Yet imagine the reaction if a substance were found to improve attention, boost memory, offer possible neuroprotection, reduce stress, and enhance cognitive function in certain patient groups. Researchers would pursue it vigorously. Venture capitalists would back startups developing novel delivery methods. Media outlets would headline its therapeutic promise.
Caffeine, by contrast, arrived with the traditions of coffeehouses, tea rituals, and daily routines. Nicotine, however, arrived tagged with the cigarette. One became socially acceptable; the other acquired a moral stigma.
That distinction has profoundly affected public policy.
A Dual Standard on Nicotine
We should continue to scrutinize nicotine carefully, of course. Every psychoactive substance involves compromises. Nicotine can be addictive and may raise heart rate and blood pressure. Some individuals experience adverse effects. Adolescents, in particular, should avoid nicotine products because developing brains may be especially vulnerable to nicotine’s influences.
Nevertheless, public health authorities themselves implicitly acknowledge nicotine’s relative safety whenever they promote nicotine replacement therapies. Millions of smokers have been encouraged to use nicotine gum, patches, lozenges, inhalers, and sprays for extended periods. Many continue to use them for months or years. If nicotine truly were the grave threat often depicted, such recommendations would be hard to justify.
Again, the caffeine comparison is instructive. Both are psychoactive stimulants. Both can foster dependence in some users. Both can trigger withdrawal. Both may elevate heart rate and blood pressure. Yet no one suggests constructing a “caffeine-free generation.”
No government is considering lifetime bans on coffee purchases for adults born after a given date. Public health bodies do not issue urgent warnings about the dangers of flavored espresso drinks attracting teenagers.
Moreover, adults do not need to demonstrate a therapeutic benefit before consuming coffee or enjoying a cocktail. Nor should they have to prove that nicotine improves their memory or concentration before using it. The potential benefits of nicotine complicate today’s policy justifications, but individual autonomy does not depend on proving them.
The Emergence of a Nicotine Phobia
Call it nicotinophobia: a revulsion to nicotine rooted less in evidence about the drug and more in its long-standing association with smoking. This fear treats nicotine not as a substance with risks and benefits to weigh, but as a contaminant whose mere presence warrants restriction.
In May, the World Health Organization urged governments to “protect young people from addiction to tobacco and nicotine products.” The U.S. Department of Health and Human Services warned last year about an “ongoing youth vaping epidemic,” even as it acknowledged continuing declines in youth vaping. The American Lung Association maintains that no level of youth tobacco use is acceptable and urges people to “quit all nicotine and tobacco products for good.” The Campaign for Tobacco-Free Kids advocates broad limits on flavored nicotine products and has condemned the FDA’s authorizations of flavored vaping products for adults.
Perhaps the larger narrative behind these developments is that some policymakers are shifting away from simply reducing smoking-related illness toward the elimination of nicotine use itself.
Massachusetts has become a testing ground for this approach. As The Examination recently noted, an increasing number of Massachusetts towns have adopted “nicotine-free generation” policies that permanently ban the sale of nicotine products to people born after a certain date, even after they reach adulthood. In June, Guy Bentley reported that public records show state-funded health officials and activists mobilized local supporters, including parents and teens, to testify in favor of the bans.
Massachusetts state Sen. Jason Lewis (D–Middlesex) advocates expanding this concept statewide. Last year he introduced a bill that would forbid nicotine product sales to anyone born after 2005. Under such a regime, a 45-year-old born in 2006 could be barred from buying nicotine pouches, snus, or electronic cigarettes, while an older neighbor could legally purchase the same items.
Notably, these proposals typically exclude nicotine gum and nicotine patches. The exception hints that the target is not nicotine by itself, but nicotine used beyond smoking cessation purposes.
Once nicotine itself becomes the central concern, harm reduction ceases to be the guiding principle. The goal becomes reducing nicotine use for its own sake.
The Iron Rule Behind Prohibition
When policymakers attempt to ban valued products, consumers rarely quit them entirely. They seek alternatives. Entrepreneurs adapt. Markets shift. Regulators respond. The cycle repeats.
Rather than erasing demand, prohibition often spurs the creation of alternative products that are more potent, less familiar, and less studied. Some drug-policy scholars describe this pattern as the “iron law of prohibition”: stricter enforcement makes the drug more potent in practice.
Nicotine policy could be following a similar trajectory. As authorities stiffen restrictions on nicotine products, producers have introduced synthetic nicotine analogs that escape traditional regulatory regimes. Some researchers worry that compounds like 6-methyl nicotine could prove more powerful than nicotine itself. Policies driven by hostility toward nicotine may push people toward substances whose risks are less clearly understood.
Public health authorities may have become victims of their own success. Their campaign against smoking was so effective that many people no longer distinguish between smoking and nicotine. Now they risk a second mistake: equating the presence of risk with the absence of benefit. If nicotine proves truly useful for many adults, we should separate it from smoking and view it as a common stimulant, not a public menace.
